Inotek Pharmaceuticals is focused on developing innovative drugs for eye diseases with a major emphasis on glaucoma; its lead candidate is trabodenoson, a drop‑administered drug currently in Phase 2. Trabodenoson is designed to increase aqueous humor outflow through the eye’s trabecular meshwork, a mechanism differentiated from existing prostaglandins and other approved therapies. Preclinical work and mechanistic studies indicate the drug up‑regulates proteases in the trabecular meshwork to clear proteinaceous blockages and restore outflow. A recently completed multi‑dose Phase 2 monotherapy study showed significant IOP reduction in the range of market‑leading prostaglandins such as latanoprost, and the drug was reported to be safe and well tolerated. Inotek plans to initiate a Phase 2 study later this year to evaluate trabodenoson in combination with latanoprost for patients inadequately controlled on latanoprost alone. Financially, the company closed a $21 million equity financing and concurrently secured $7 million in venture debt to advance ongoing clinical development; the company is located in Lexington, MA. Inotek Pharmaceuticals is a Lexington, Massachusetts-based developer of innovative drug candidates to address significant diseases of the eye. Its lead program is INO-8875, an investigational eye-drop for glaucoma. In an earlier Phase 1/2 trial, INO-8875 was shown to significantly reduce intraocular pressure in glaucoma patients. The company plans to advance INO-8875 into multiple-dose Phase 2 clinical trials. To support that work it closed an $18M preferred stock financing. As part of the round, John Leaman joined Inotek’s board of directors.

Total raised

$46M

Funding rounds

3

Latest round

Equity

Latest activity

Sep 2013